ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.662,38
0,08%
S&P 500
5.431,60
-0,04%
US Dollar vs BRL
5,35089
0,01%
Bitcoin
66.352,35
-0,43%
Brent Oil
81,975
-0,18%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Europa
  5. EU
  6. Transgene SA (TNG)

  7. Transgene SA (TNG) Notícias

TNG

Transgene (TNG)

Transgene SA
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:EU:TNG
DataHoraFonteTítuloCódigoCompanhia
03/06/202402:30GlobeNewswire Inc.Transgene – Premier patient inclus dans la partie Phase II de l’étude randomisée de Phase I/II de son actif phare TG4050, un vaccin thérapeutique individualisé évalué dans les cancers de la tête et du couEU:TNGTransgene SA
03/06/202402:30GlobeNewswire Inc.Transgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck CancerEU:TNGTransgene SA
15/05/202412:45GlobeNewswire Inc.Transgene’s Combined General Meeting of May 15, 2024EU:TNGTransgene SA
15/05/202412:45GlobeNewswire Inc.Assemblée Générale Mixte de Transgene du 15 mai 2024EU:TNGTransgene SA
14/05/202412:45GlobeNewswire Inc.Transgene provides business and financial update for Q1 2024EU:TNGTransgene SA
14/05/202412:45GlobeNewswire Inc.Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024EU:TNGTransgene SA
24/04/202412:45GlobeNewswire Inc.Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024EU:TNGTransgene SA
24/04/202412:45GlobeNewswire Inc.Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024EU:TNGTransgene SA
11/04/202414:05GlobeNewswire Inc.Document d'enregistrement Universel 2023EU:TNGTransgene SA
11/04/202412:45GlobeNewswire Inc.MIse à disposition du document d'enregistrement universel 2023 de TransgeneEU:TNGTransgene SA
11/04/202412:45GlobeNewswire Inc.Availability of Transgene's 2023 Universal Registration DocumentEU:TNGTransgene SA
09/04/202412:45GlobeNewswire Inc.Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024EU:TNGTransgene SA
09/04/202412:45GlobeNewswire Inc.Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024EU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025EU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025EU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources OfficerEU:TNGTransgene SA
27/03/202413:45GlobeNewswire Inc.Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources HumainesEU:TNGTransgene SA
18/03/202413:45GlobeNewswire Inc.Transgene Announces Upcoming Investor MeetingsEU:TNGTransgene SA
18/03/202413:45GlobeNewswire Inc.Transgene annonce ses prochaines rencontres avec les investisseursEU:TNGTransgene SA
06/03/202403:30GlobeNewswire Inc.Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024EU:TNGTransgene SA
06/03/202403:30GlobeNewswire Inc.Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024EU:TNGTransgene SA
05/03/202403:30GlobeNewswire Inc.Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050EU:TNGTransgene SA
05/03/202403:30GlobeNewswire Inc.Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050EU:TNGTransgene SA
22/01/202413:45GlobeNewswire Inc.Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business OfficerEU:TNGTransgene SA
22/01/202413:45GlobeNewswire Inc.Transgene annonce la nomination de James Wentworth comme Directeur du Business DevelopmentEU:TNGTransgene SA
22/01/202404:00GlobeNewswire Inc.Transgene présente son calendrier de communication financière pour 2024EU:TNGTransgene SA
22/01/202404:00GlobeNewswire Inc.Transgene Announces Financial Calendar for 2024EU:TNGTransgene SA
08/01/202413:45GlobeNewswire Inc.Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050EU:TNGTransgene SA
08/01/202413:45GlobeNewswire Inc.Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancerEU:TNGTransgene SA
04/01/202413:45GlobeNewswire Inc.Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023EU:TNGTransgene SA
 Apresentando as notícias mais relevantes sobre:EU:TNG

Seu Histórico Recente

BOV
HBOR3
HELBOR ON
BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados